A SGLT2 inhibitor dapagliflozin prevents heart failure with preserved ejection fraction through activating mitophagy in ZDF diabetic rats

被引：0
|
作者：
Feng, B. [1 ]
Zhang, N. [2 ]
Shi, B. [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 1, Endocrinol & Metab, Suzhou, Peoples R China
[2] Nanjing Med Univ, Affiliated Soochow Hosp, Cardiol, Suzhou, Peoples R China
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
198
引用
收藏
页码：S101 / S101
页数：1
相关论文
共 50 条
  • [41] The SGLT2 Inhibitor Dapagliflozin Prevents the Loss of Pancreatic Function in the High Fat Fed Female (HFFF) ZDF Rat
    Macdonald, Ruth F.
    Westgate, Leanne
    Poucher, Simon M.
    Mayers, Rachel M.
    Whaley, Jean M.
    DIABETES, 2009, 58 : A380 - A381
  • [42] SGLT2 inhibitors are associated with development of heart failure with improved ejection fraction
    Yang, C. D.
    Wang, X. Q.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [43] Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction
    Mouhamed Nashawi
    Omar Sheikh
    Ayman Battisha
    Mahnoor Mir
    Robert Chilton
    Heart Failure Reviews, 2022, 27 : 219 - 234
  • [44] Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction
    Nashawi, Mouhamed
    Sheikh, Omar
    Battisha, Ayman
    Mir, Mahnoor
    Chilton, Robert
    HEART FAILURE REVIEWS, 2022, 27 (01) : 219 - 234
  • [45] SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
    Raschi, Emanuel
    Fadini, Gian Paolo
    Diemberger, Igor
    Poluzzi, Elisabetta
    De Ponti, Fabrizio
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (05) : 647 - 650
  • [46] Cardiac remodeling with SGLT2 inhibitors in heart failure with reduced ejection fraction
    Romeo, Francisco J.
    Del Buono, Marco G.
    Aguilar-gallardo, Jose S.
    Lorente-ros, Marta
    Damonte, Juan I.
    Chiabrando, Juan G.
    Dixon, Dave L.
    Biondi-zoccai, Giuseppe
    Abbate, Antonio
    Carbone, Salvatore
    MINERVA CARDIOLOGY AND ANGIOLOGY, 2024, 72 (01) : 95 - 97
  • [47] Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
    Whaley, Jean
    Hagan, Deborah
    Taylor, Joseph
    Xin, Li
    Han, Songping
    Meng, Wei
    Ellsworth, Bruce
    Sher, Philip
    McCann, Peggy
    Wu, Gang
    Biller, Scott
    Wetterau, John
    Washburn, William
    DIABETES, 2007, 56 : A149 - A149
  • [48] Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
    Han, Songping
    Hagan, Deborah L.
    Taylor, Joseph R.
    Xin, Li
    Meng, Wei
    Biller, Scott A.
    Wetterau, John R.
    Washburn, William N.
    Whaley, Jean M.
    DIABETES, 2008, 57 (06) : 1723 - 1729
  • [49] Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction
    Selvaraj, Senthil
    Patel, Shachi
    Sauer, Andrew J.
    McGarrah, Robert W.
    Jones, Philip
    Kwee, Lydia Coulter
    Windsor, Sheryl L.
    Ilkayeva, Olga
    Muehlbauer, Michael J.
    Newgard, Christopher B.
    Borlaug, Barry A.
    Kitzman, Dalane W.
    Shah, Sanjiv J.
    Shah, Svati H.
    Kosiborod, Mikhail N.
    JACC-HEART FAILURE, 2024, 12 (06) : 999 - 1011
  • [50] Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
    David M. Williams
    Marc Evans
    Diabetes Therapy, 2020, 11 : 2207 - 2219
12345